Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,522.00
(
0.33%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,553.34
(
0.25%
)
News Focus
News Focus
Post# of 50
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

whytestocks

Send PM Follow Ignore
Followers 131
Posts 15004
Boards Moderated 0
Alias Born 06/04/2018

whytestocks

Re: None

Thursday, 07/04/2019 12:10:21 PM

Thursday, July 04, 2019 12:10:21 PM

Post# of 50
News: $GRFS Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

BARCELONA, Spain , July 4, 2019 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify ® , its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (F...

Read the whole news Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent GRFS News
More GRFS News